Supernus Pharmaceuticals Research and Development Expenses 2011-2024 | SUPN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Supernus Pharmaceuticals research and development expenses from 2011 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

Supernus Pharmaceuticals Research and Development Expenses 2011-2024 | SUPN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Supernus Pharmaceuticals research and development expenses from 2011 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$19B
Dr Reddy's Laboratories (RDY)	$12B
BridgeBio Pharma (BBIO)	$4.3B
Bausch Health Cos (BHC)	$3B
Amphastar Pharmaceuticals (AMPH)	$2.1B
Taysha Gene Therapies (TSHA)	$434M
Personalis (PSNL)	$261M
Assembly Biosciences (ASMB)	$98M
Sol-Gel Technologies (SLGL)	$12M
Evoke Pharma (EVOK)	$7M
Teligent (TLGT)	$0M